We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Point-Of-Care Test to Transform Early-Stage Cervical Cancer Diagnosis

By LabMedica International staff writers
Posted on 27 Jun 2025

Cervical cancer is the world’s fourth most common cancer in women. More...

When it’s found early, it’s one of the most preventable and treatable cancers. The main screening method is an in-person Pap smear. The FDA recently approved the first at-home self-collection device, which screens for HPV, the virus that causes nearly all cervical cancers. Still, these methods can be expensive, time-consuming, and not always available. Now, a new method based on measuring cellular proteins could reduce the need for expensive laboratory equipment and training.

Researchers are now one step closer to developing a simple, at-home test to prevent cervical cancer or treat it early, according to a new study by researchers from the University of Florida Health Cancer Center (Gainesville, FL, USA) and Purdue University (West Lafayette, IN, USA). In the new study, researchers validated four proteins that were more abundant in swabs from women with high-grade precancerous lesions and tissue samples from patients. The results, published in the journal Cancers, show that the researchers found the proteins could be used as sensitive and specific biomarkers to indicate precancerous lesions and to distinguish subtypes of cervical cancer.

Precancerous lesions can usually be successfully treated, preventing cancer from developing. Knowing the subtype tells health care providers how aggressive or fast-moving the cancer is, helping them develop a treatment plan. Next, the researchers plan to develop a standardized way to collect and process cervical cancer samples, paving the way for a point-of-care test. Point-of-care tests are portable tests that can be done in more convenient settings than a traditional medical laboratory, and they’re usually faster.

“Our results pave the way for us to develop inexpensive, fast and accurate preliminary screening tests for cervical cancer,” said Sulma Mohammed, D.V.M., Ph.D., the study’s senior author. “This test has the potential to transform early-stage cervical cancer diagnosis and treatment, particularly in areas with limited access to health care.”

Related Links:
UF Health Cancer Center 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.